Baseline characteristics of the two groups
| BDP/F# | BUD/F | |
| Male | 45 (42.1) | 46 (42.2) |
| Female | 62 (57.9) | 63 (57.8) |
| Age yrs | 43.4±12.3 | 46.0±11.1 |
| Weight kg | 72.2±12.9 | 75.6±16.3 |
| Height cm | 168.8±9.6 | 168.7±9.8 |
| Allergies | 69 (64.5) | 70 (64.2) |
| ICS dose μg BDP equivalent | 787.9±257.2 | 808.0±262.7 |
| Time from first diagnosis yrs | 11.8±9.5 | 12.4±10.4 |
| FEV1 % pred | 70.5±10.7 | 69.3±9.7 |
| FEV1 L | 2.30±0.71 | 2.21±0.64 |
| FEV1 % change in reversibility test | 23.6±10.1 | 26.5±12.1 |
| Morning PEF L·min−1 | 308.9±106.6 | 305.2±100.0 |
| Evening PEF L·min−1 | 317.5±112.1 | 315.0±98.5 |
Data are presented as n (%) and mean±sd. BDP/F: Beclomethasone/formoterol; BUD/F: budesonide/formoterol; ICS: inhaled corticosteroids; FEV1: forced expiratory volume in one second; % pred: % predicted; PEF: peak expiratory flow. The p-values were considered nonsignificant between groups for all comparisons. #: two patients were excluded from the intention-to-treat population due to missing post-baseline data.